GLB-002

Primary objectives: (1) To evaluate the safety and tolerability of GLB-002 in subjects with relapsed or refractory non-Hodgkin's lymphoma (R/R NHL); (2) To determine the recommended Phase II dose (RP2D) of GLB-002 for the treatment of R/R NHL subjects; (3) To evaluate the efficacy of GLB-002 at the recommended extended dose (RED) in the treatment of R/R NHL subjects. Secondary objectives: (1) To evaluate the pharmacokinetic (PK) characteristics of GLB-002 and its R enantiomer in R/R NHL subjects; (2) To evaluate the safety of GLB-002 in R/R NHL subjects.